Table 2.

Significantly altered biological pathways in the Hep3B, HepG2, and Huh7 cell lines compared to human livers.

Hep3B vs HLM			HepG2 vs HLM			Huh7vs HLM
Pathway name	q-value	Trend	Pathway name	q-value	Trend	Pathway name	q-value	Trend
Non-alcoholic fatty liver disease	6.0E−03	↓	Chemical carcinogenesis	4.5E−04	↓	Ribosome	5.4E−05	↑
Metabolism of xenobiotics by cytochrome P450	6.0E−03	↓	Metabolism of xenobiotics by cytochrome P450	5.2E−04	↓	Metabolism of xenobiotics by cytochrome P450	2.2E−04	↓
Steroid hormone biosynthesis	7.0E−03	↓	Parkinson’s disease	7.0E−03	↓	Drug metabolism-cytochrome P450	2.0E−03	↓
Alzheimer’s disease	7.0E−03	↓	Alzheimer’s disease	7.0E−03	↓	Alzheimer’s disease	2.0E−03	↓
Spliceosome	9.0E−03	↑	Drug metabolism-cytochrome P450	1.9E−02	↓	Steroid hormone biosynthesis	3.0E−03	↓
Drug metabolism-cytochrome P450	1.2E−02	↓	Metabolic pathways	1.9E−02	↓	Chemical carcinogenesis	5.0E−03	↓
Metabolic pathways	1.3E−02	↓	Biosynthesis of amino acids	1.9E−02	↓	Non-alcoholic fatty liver disease	2.4E−02	↓
Peroxisome	1.5E−02	↓	Non-alcoholic fatty liver disease	1.9E−02	↓	Drug metabolism - other enzymes	2.6E−02	↓
Chemical carcinogenesis	2.7E−02	↓	Spliceosome	2.3E−02	↑	Retinol metabolism	3.8E−02	↓
Parkinson’s disease	2.9E−02	↓	Drug metabolism - other enzymes	3.0E−02	↓	Spliceosome	3.9E−02	↑
Oxidative phosphorylation	3.4E−02	↓	Steroid hormone biosynthesis	3.0E−02	↓	Parkinson’s disease	4.5E−02	↓
mRNA surveillance pathway	4.0E−02	↑